Does reversing prediabetes actually protect your heart?
Yes. In post-hoc analyses of two landmark prevention trials, people with prediabetes who returned to normal glucose regulation had about half the risk of cardiovascular death or hospitalisation for heart failure, with a fully adjusted hazard ratio of 0.41 (95% CI 0.20 to 0.84) in the US cohort. The Chinese cohort showed the same direction, with a hazard ratio of 0.49 (95% CI 0.28 to 0.84).
Prediabetes means your blood sugar is higher than normal but not yet high enough to be called diabetes. It is a warning sign, not a final verdict. This analysis asked whether pushing blood sugar back into the normal range translates into fewer cardiac events over the long run. The answer was yes, and the benefit persisted for decades.
What the data show
Researchers ran post-hoc analyses of long-term follow-up from two of the most important diabetes prevention studies ever conducted. One was the US Diabetes Prevention Program Outcomes Study, with 2402 participants followed from the start of the original trial on July 31, 1996 through the end of phase 3 on February 23, 2020. The other was China’s Da Qing Diabetes Prevention Outcomes Study, with 540 participants. Remission was defined by American Diabetes Association criteria, assessed after 1 year of intervention in the US study and after 6 years in the Chinese study.
Remission was uncommon. In the US cohort, 275 of 2402 participants (11.5%) reached it after 1 year, while 2127 (88.5%) did not. Over a median follow-up of 20 years, the event rate for cardiovascular death or heart failure hospitalisation was 1.74 per 1000 person-years (95% CI 0.87 to 3.48) in those who reached remission versus 4.17 per 1000 person-years (95% CI 3.55 to 4.89) in those who did not (p=0.013). The fully adjusted hazard ratio was 0.41 (95% CI 0.20 to 0.84; p=0.014).
The Chinese cohort, followed over 30 years, confirmed the pattern with a hazard ratio of 0.49 (95% CI 0.28 to 0.84; p=0.010), and a pooled meta-analysis across both datasets supported the result. When the analysis counted anyone who reached remission at least once during follow-up, the hazard ratio for the composite endpoint was 0.43 (95% CI 0.29 to 0.63; p<0.0001).
One point deserves emphasis. The comparison here was between people who actually reached remission and people who did not. The endpoint was cardiovascular death or hospitalisation for heart failure, not heart attack or stroke.
Dr. Kumar’s Take
I find this analysis encouraging because it points to a concrete, measurable goal. For years I have told patients with prediabetes to eat better and move more, which remains good advice. This work suggests the prize is reaching normal glucose regulation, and that reframes the conversation. The target is the number, and the lifestyle work is how you get there.
I do want to be honest about what this is. These are post-hoc analyses, meaning the investigators looked back at data from trials originally designed to answer other questions. That kind of analysis can show strong associations but cannot fully establish cause and effect. People who reach remission may differ in other ways that also protect their hearts, and only about one in nine participants in the US cohort reached remission at the 1 year mark, so this is not an easy target. Still, seeing the same pattern in two very different populations, over 20 and 30 years respectively, is the kind of consistency that makes me pay attention.
How the studies were done
Both trials enrolled people with prediabetes and followed them for a very long time. The Da Qing study in China contributed 30 years of follow-up. The US study contributed a median of 20 years. Remission was defined using American Diabetes Association criteria and assessed after 1 year of intervention in the US study and after 6 years in the Chinese study.
The primary endpoint in both was cardiovascular death or hospitalisation for heart failure. In the US study, inverse probability of treatment weighting was used to adjust for baseline differences between the groups, and a unifying meta-analysis was calculated across both datasets for the primary endpoint and for all-cause mortality. Because the data come from real trial participants tracked over decades, the findings reflect what happened in actual human lives rather than a short laboratory experiment. That long horizon matters, since heart disease takes years to develop and many studies are too brief to capture it.
Who this matters for
If you have been told you have prediabetes, this research is directly relevant to you. It suggests that the work you put into your blood sugar may pay off in your heart over the long run. It is also relevant for anyone with a family history of diabetes or heart disease, since prediabetes is common and often produces no symptoms. Prediabetes is a turning point, not a dead end, and the direction you turn may shape your cardiovascular health for decades.
Practical Takeaways
- Ask your doctor for your fasting glucose and A1C numbers, and set a clear goal of returning them to the normal range rather than just slowing their rise.
- Focus on changes that move the actual numbers, such as steady weight loss, regular activity, and cutting back on sugary drinks and refined carbs, then recheck your blood sugar to confirm progress.
- Treat a return to normal glucose regulation as a result worth maintaining, since the benefit in this analysis was tied to reaching remission.
- Keep up regular checkups even after you reach normal blood sugar, because glucose can drift back up and ongoing monitoring tells you where you stand.
Related Studies and Research
- A gentle Chinese exercise lowers blood pressure as well as brisk walking
- Can fiber lower your risk of heart disease? What 31 meta-analyses say
- Treating gout properly may cut heart attack and stroke risk by up to 23%
- What this Romanian study reveals about metabolic syndrome and heart disease risk
FAQs
What counts as prediabetes remission?
In this analysis, remission meant restoring normal glucose regulation, assessed using American Diabetes Association criteria. It was measured after 1 year of intervention in the US study and after 6 years in the Chinese study. Remission was the milestone linked to better heart outcomes. It is worth asking your doctor exactly which numbers they are using and when they plan to recheck them.
How long do the heart benefits last?
The association was durable. In the US cohort it held over a median of 20 years of follow-up, and in the Chinese cohort over 30 years. That long timeline is one of the most notable features of this work, since many studies follow people for only a few years. The authors describe the benefit as a decades-long legacy effect.
What exactly was the heart outcome measured?
The primary endpoint was cardiovascular death or hospitalisation for heart failure. This analysis did not report on heart attack or stroke, so the findings should be read as being about cardiovascular death and heart failure admissions specifically.
Bottom Line
Reaching prediabetes remission was associated with roughly half the risk of cardiovascular death or hospitalisation for heart failure: a hazard ratio of 0.41 in the US cohort over a median 20 years, 0.49 in the Chinese cohort over 30 years, and 0.43 for anyone reaching remission at least once during follow-up. These are post-hoc analyses, so they show association rather than proof of cause. If you have prediabetes, returning your glucose to the normal range looks like a goal worth chasing and holding onto.
